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Dr Pevec (Sacramento, Calif). Captain Arthurs and colleagues
have presented a prospective observational study evaluating the
association of C-reactive protein with the progression of carotid
stenosis. This study, including 271 patients over 3 years, provides
valuable information on the association of CRP and inflammatory
markers and the progression of atherosclerosis. The authors are to
be commended for conducting this longitudinal study. The au-
thors suggest that elevated CRP levels predict progression of
carotid artery stenosis and that the measurement of CRP in pa-
tients with carotid artery stenosis may be of some clinical benefit.
I have several questions. Patients with CRP in the highest
quartile were found to be at higher risk for progression of carotid
artery stenosis. The CRP quartiles were assigned retrospectively by
taking the average of the CRP measurements obtained from each
study patient every 6 months. While this is useful in helping to
understand the relationship of CRP with progression of carotid
stenosis in general, looking retrospectively at an average of values
measured over several years, there is not a benefit in predicting
future progression of stenosis in an individual patient. Is there a
single cutoff value of CRP that can be used to predict progression
of carotid stenosis? Can the authors provide positive- and negative-
predictive values for some level of CRP, for instance, greater than
6 mg/dL, which was their level in the fourth quartile?
The authors defined progression of carotid stenosis in two
ways. Type A included progression from any category of stenosis to
a higher category of stenosis. Type B included only stenosis that
progressed to 50% or greater or from 50% to 79% to a greater
stenosis. The authors do not state how they define the categories of
stenosis, but as the authors are from Washington, one can assume
they use the Strandness criteria. If this is true, progression from 0%
to 15% to 16% to 49% stenosis is based upon subjective criteria—
plaque appearance and presence of spectral broadening—while
progression to a greater than 50% stenosis is based on objective
velocity criteria. While type B progression based on objective
duplex velocity measurements correlated with elevated CRP levels
on univariate analysis, this correlation was not significant on mul-
tivariate analysis. Only when progression based upon subjective
duplex assessment was included, so-called type A progression, were
elevated CRP levels predictive on multivariate analysis. A full 41%
of study patients had 0% to 15% carotid stenosis at entry. Lack of
independent correlation of elevated CRP with objective progres-
sion of carotid stenosis seems to greatly weaken the importance of
these findings. Can the authors comment on this please?
Finally, is the measurement of CRP of clinical benefit in the
management of patients with carotid stenosis? In the paper the
authors suggest that decreasing inflammation with aspirin and/or
statins may be of benefit in patients with carotid stenosis and
elevated CRP. Shouldn’t all patients with carotid stenosis be on
aspirin and a statin drug?
I would like to compliment the authors on a well-performed
and well-presented study that increases our understanding of the
influence of inflammation on progression of atherosclerosis. I
would like to thank the authors for providing me with a copy of
their manuscript in advance of the meeting, and I would like to
thank the program committee for the privilege of discussing this
paper. Thank you.
Dr Arthurs. I would like to thank Dr Pevec for his insightful
comments. I will start with his second question first as it addresses
the matter of our design of the study and the difficulty in doing so
from the onset. It comes down to the subjective nature of mild vs
moderate disease on duplex and whether that plays a part in the
study. It absolutely does. It is extremely subjective, and we at-
tempted to control for that variability. That is why we excluded all
patients with less than three examinations, so the patient either had
two normal examinations with one abnormal examination on the
third study, or the patient had a normal study with two subsequent
examinations read out as moderate by the same two vascular
technicians. In addition, during this time, the same two vascular
staff surgeons read the examinations. Because our ultimate goal
with this study was observational evaluation of progression of
patients with subclinical disease, we felt that more sensitive imag-
ing modalities would not justify the cost of performing examina-
tions at 6-month intervals.
His second question—ultimately is there a cutoff value for
CRP? I think if we look at where the coronary literature has utilized
CRP, the CRP values that are abnormal are not far from the
definitions utilized for abnormal CRP. In our study, 6 is the cutoff,
but ultimately, that just applies to this cohort. I think the message
is that we were not trying to identify patients that had high-grade
stenosis. We were looking at that population of patients that either
came with no stenosis or had aminimal stenosis withminimal to no
risk factors. From our study, CRP may be most applicable in those
patients without any risk factors and minimal carotid disease who
have a CRP level above 6. They appear to be at higher risk for
progression of disease based on our findings. We are trying to
quantify the idea that there is inflammation as a marker of overall
disease risk or patient vulnerability.
That rolls into the third question of shouldn’t all patients who
have carotid artery stenosis be on a statin or aspirin. Absolutely.
However, a patient has no risk factors, no lesion on examination,
but comes into our office and has a CRP level that is persistently
elevated, whether it be 4 mg/dL or 6 mg/dL, should there be
different goals in medical treatment for that patient? We can’t
answer that question with this study, but based on our study, those
patients are at a higher risk of carotid stenosis progression. Finally,
if a patient has a normal LDL and an elevated CRP, should you
treat that patient with a statin or some other anti-inflammatory
modality? Thank you.
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